Clinical Trial: A Clinical Study on the First-line Treatment of Metastatic Pancreatic Cancer With TQB2916 Injection Combined With Gemcitabine Hydrochloride for Injection and Paclitaxel for Injection (Albumin-bound Type)

U.S., May 9 -- ClinicalTrials.gov registry received information related to the study (NCT06962267) titled 'A Clinical Study on the First-line Treatment of Metastatic Pancreatic Cancer With TQB2916 Injection Combined With Gemcitabine Hydrochloride for Injection and Paclitaxel for Injection (Albumin-bound Type)' on April 30.

Brief Summary: This trial was a single-arm, open-label design to evaluate the efficacy and safety of "TQB2916+ gemcitabine + albumin-paclitaxel" as the first-line treatment for metastatic pancreatic cancer.

Study Start Date: April 18

Study Type: INTERVENTIONAL

Condition: Pancreatic Cancer

Intervention: DRUG: TQB2916 Injection

A Phase II clinical study to evaluate the efficacy and safety of TQB2916 injection combin...